Rebeqa Gunnarsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebeqa Gunnarsson has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Andrea Biloglav
Division of Clinical Genetics, Department of Laboratory Medicine Lund University Lund Sweden
5 shared publicationsBertil Johansson
Division of Clinical Genetics, Department of Laboratory Medicine Lund University Lund Sweden
5 shared publicationsAnders Castor
Department of Pediatrics Skåne University Hospital Lund Sweden
4 shared publications- Minjun Yang
Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
4 shared publications - Kajsa Paulsson
Department of Laboratory Medicine, Division of Clinical Genetics Lund University Lund Sweden
3 shared publications Thoas Fioretos
Division of Clinical Genetics, Department of Laboratory Medicine Lund University Lund Sweden
3 shared publications
Latest Publications
- Open Access
- 19 May 2025
- Published by Wiley in HemaSphere
- Vol. 9 (5)
Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
- 19 May 2025
- Published by Wiley in HemaSphere
- Vol. 9 (5)
Open AccessMutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
- Open Access
- 1 April 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (6) , 1681-1684
Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia
- 1 April 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (6) , 1681-1684
Open AccessSingle base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia
- Open Access
- 16 April 2021
- Published by Springer Nature in Leukemia
- Vol. 35 (5) , 1485-1489
Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing
- 16 April 2021
- Published by Springer Nature in Leukemia
- Vol. 35 (5) , 1485-1489
Open AccessSingle base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing
- Open Access
- 12 March 2018
- Published by Springer Nature in Leukemia
- Vol. 32 (10) , 2117-2125
Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia
High-throughput sequencing was applied to investigate the mutation/methylation patterns on 1q and gene expression profiles in pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL) with/without (w/wo) dup(1q). Sequencing of the breakpoint regions and all exons on 1q in seven dup(1q)-positive cases revealed non-synonymous somatic single nucleotide variants (SNVs) in BLZF1, FMN2, KCNT2, LCE1C, NES, and PARP1. Deep sequencing of these in a validation cohort w (n = 17)/wo (n = 94) dup(1q) revealed similar SNV frequencies in the two groups (47% vs. 35%; P = 0.42). Only 0.6% of the 36,259 CpGs on 1q were differentially methylated between cases w (n = 14)/wo (n = 13) dup(1q). RNA sequencing of high hyperdiploid (HeH) and t(1;19)(q23;p13)-positive cases w (n = 14)/wo (n = 52) dup(1q) identified 252 and 424 differentially expressed genes, respectively; only seven overlapped. Of the overexpressed genes in the HeH and t(1;19) groups, 23 and 31%, respectively, mapped to 1q; 60-80% of these encode nucleic acid/protein binding factors or proteins with catalytic activity. We conclude that the pathogenetically important consequence of dup(1q) in BCP ALL is a gene-dosage effect, with the deregulated genes differing between genetic subtypes, but involving similar molecular functions, biological processes, and protein classes.
- 12 March 2018
- Published by Springer Nature in Leukemia
- Vol. 32 (10) , 2117-2125
Open AccessMutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia
High-throughput sequencing was applied to investigate the mutation/methylation patterns on 1q and gene expression profiles in pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL) with/without (w/wo) dup(1q). Sequencing of the breakpoint regions and all exons on 1q in seven dup(1q)-positive cases revealed non-synonymous somatic single nucleotide variants (SNVs) in BLZF1, FMN2, KCNT2, LCE1C, NES, and PARP1. Deep sequencing of these in a validation cohort w (n = 17)/wo (n = 94) dup(1q) revealed similar SNV frequencies in the two groups (47% vs. 35%; P = 0.42). Only 0.6% of the 36,259 CpGs on 1q were differentially methylated between cases w (n = 14)/wo (n = 13) dup(1q). RNA sequencing of high hyperdiploid (HeH) and t(1;19)(q23;p13)-positive cases w (n = 14)/wo (n = 52) dup(1q) identified 252 and 424 differentially expressed genes, respectively; only seven overlapped. Of the overexpressed genes in the HeH and t(1;19) groups, 23 and 31%, respectively, mapped to 1q; 60-80% of these encode nucleic acid/protein binding factors or proteins with catalytic activity. We conclude that the pathogenetically important consequence of dup(1q) in BCP ALL is a gene-dosage effect, with the deregulated genes differing between genetic subtypes, but involving similar molecular functions, biological processes, and protein classes.
- Open Access
- 4 June 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 274
NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients
NOTCH1 PEST domain mutations in chronic lymphocytic leukemia have recently been shown to be of prognostic relevance. Both NOTCH1 and NOTCH2 are constitutively activated in B-cell CLL but not expressed in normal B cells and may be involved in survival and resistance to apoptosis in CLL. We screened for mutations in different parts of both NOTCH1 and NOTCH2 genes and related the changes to survival and other known risk factors. In a cohort of 209 CLL patients, we used single strand conformation analysis to determine which of the samples carrying the NOTCH mutations and direct dideoxy sequencing was used to determine the exact nucleotide changes. Kaplan-Meier curves and log rank test were used to determine overall survival for NOTCH1 mutated cases and Cox regression analysis was used to calculate hazardous ratios. In the present study, we found NOTCH1 PEST domain mutations in 6.7% of the cases. A shorter overall survival was found in patients with NOTCH1 mutations compared to wildtype (p = 0.049). Further, we also examined the extracellular and the heterodimerisation domains of the NOTCH1 gene and the PEST domain and heterodimerisation domain of the NOTCH2 gene, but no mutations were found in these regions. NOTCH1 mutations were most commonly observed in patients with unmutated IGHV gene (10/14), and associated with a more aggressive disease course. In addition, NOTCH1 mutations were almost mutually exclusive with TP53 mutations. In the combined group of NOTCH1 (6.7%) or TP53 (6.2%) mutations, a significant difference in overall survival compared to the wildtype NOTCH1 and TP53 was found (p = 0.002). Both NOTCH1 and TP53 mutations seem to be independent predictive markers for worse outcome in CLL-patients and this study emphasizes the contention that NOTCH1 mutations is a novel risk marker.
- 4 June 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 274
Open AccessNOTCH1 mutations influence survival in chronic lymphocytic leukemia patients
NOTCH1 PEST domain mutations in chronic lymphocytic leukemia have recently been shown to be of prognostic relevance. Both NOTCH1 and NOTCH2 are constitutively activated in B-cell CLL but not expressed in normal B cells and may be involved in survival and resistance to apoptosis in CLL. We screened for mutations in different parts of both NOTCH1 and NOTCH2 genes and related the changes to survival and other known risk factors. In a cohort of 209 CLL patients, we used single strand conformation analysis to determine which of the samples carrying the NOTCH mutations and direct dideoxy sequencing was used to determine the exact nucleotide changes. Kaplan-Meier curves and log rank test were used to determine overall survival for NOTCH1 mutated cases and Cox regression analysis was used to calculate hazardous ratios. In the present study, we found NOTCH1 PEST domain mutations in 6.7% of the cases. A shorter overall survival was found in patients with NOTCH1 mutations compared to wildtype (p = 0.049). Further, we also examined the extracellular and the heterodimerisation domains of the NOTCH1 gene and the PEST domain and heterodimerisation domain of the NOTCH2 gene, but no mutations were found in these regions. NOTCH1 mutations were most commonly observed in patients with unmutated IGHV gene (10/14), and associated with a more aggressive disease course. In addition, NOTCH1 mutations were almost mutually exclusive with TP53 mutations. In the combined group of NOTCH1 (6.7%) or TP53 (6.2%) mutations, a significant difference in overall survival compared to the wildtype NOTCH1 and TP53 was found (p = 0.002). Both NOTCH1 and TP53 mutations seem to be independent predictive markers for worse outcome in CLL-patients and this study emphasizes the contention that NOTCH1 mutations is a novel risk marker.
- 10 September 2009
- Published by Springer Nature in Leukemia
- Vol. 24 (1) , 211-215
Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients
- 10 September 2009
- Published by Springer Nature in Leukemia
- Vol. 24 (1) , 211-215
Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients